Agenzia Italiana del Farmaco

AIFA

Certificate No: IT-API/74/H/2016

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC

The competent authority of Italy confirms the following:
The manufacturer INDUSTRIALE CHIMICA S.R.L.
Site address Via E. H. Grieg, 13 - 21047 SARONNO (VA)

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC transposed in the following national legislation: **D.L. n. 219 of 24th April 2006 art. 53**

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2016/04/08, it is considered that it complies with the Good Manufacturing Practice requirements referred to in the principles of GMP for active substances referred to in Article 47 of Directive 2001/83/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.
The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it
SIS : 1738

VI
GMP

Agenzia Italiana del Farmaco

AIFA

Part 2

Name and address of the site:

INDUSTRIALE CHIMICA S.R.L. - Via E. H. Grieg, 13, 21047 SARONNO (VA)

Name of the active Substances manufactured or imported:

11-ALPHA-HYDROXY CANRENONE
ABIRATERONE ACETATE
ALPROSTADIL
BIMATOPROST
BRINZOLAMIDE
BUDESONIDE
BUMETANIDE
DALFAMPRIDINE
DESOGESTREL
DIENOGEST
DOFETILIDE
DROSPIRENONE
EPLERENONE
ESTRADIOL HEMIHYDRATE
ESTRONE
ETHINYLESTRADIOL
ETONOGESTREL
FENOTEROL HYDROBROMIDE
PHENTOLAMINE MESYLATE
FLUTICASONE PROPIONATE
FORMOTEROL FUMARATE DIHYDRATE
FULVESTRANT
GESTODENE
GESTONORONE ACETATE
GUANFACINE HYDROCHLORIDE
IDEBENONE
INDACATEROL MALEATE
INDAPAMIDE
LATANOPROST

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it
SIS : 1738

VI
GMP

LEVONORGESTREL
LEVONORGESTREL ACETATE
LEVONORGESTREL BUTYRATO
LOTEPREDNOL ETABONATE
MEMANTINE HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE
MOMETASONE FUROATE
MOMETASONE FUROATE MONOHYDRATE
NITAZOXANIDE
NOMEGESTROL ACETATE
NORGESTIMATE
PENTAZOCINE HYDROCHLORIDE
PRASTERONE ACETATE
PREDNISOLONE
SALMETEROL XINAFOATE
SULFAMETHYLTHIAZOLE
TAFLUPROST
TIBOLONE
TIOTROPIUM BROMIDE MONOHYDRATE
TIOTROPIUM BROMIDE SOLVATE
TRAVOPROST
TRIMEGESTONE
ZOPICLONE

3 - Manufacturing Operations - Active Substances
ABIRATERONE ACETATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: Crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it
SIS : 1738

VI
GMP

	drying, milling/micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
ALPROSTADIL

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it
SIS : 1738

VI
GMP

3 - Manufacturing Operations - Active Substances
BIMATOPROST

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Prostagladins **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: Crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps Drying **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
BRINZOLAMIDE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: Crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it
SIS : 1738

VI
GMP

	drying,micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
BUDESONIDE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: Crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
BUMETANIDE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: Crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
DALFAMPRIDINE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it
SIS : 1738

VI
GMP

	3.5.3. Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
DESOGESTREL

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: Crystallizzazione
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, milling/micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
DIENOGEST

3.1	**Manufacture of Active Substance by Chemical Synthesis**

	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: Crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
DOFETILIDE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot

	numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
DROSPIRENONE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
EPLERENONE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity

	3.1.2. Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: Crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, micronisation **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
ETHINYLESTRADIOL

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)

3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
ETONOGESTREL

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
FENOTEROL HYDROBROMIDE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it
SIS : 1738

3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
PHENTOLAMINE MESYLATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it
SIS : 1738

VI
GMP

3 - Manufacturing Operations - Active Substances
FLUTICASONE PROPIONATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
FORMOTEROL FUMARATE DIHYDRATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation

	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **FULVESTRANT**	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

Agenzia Italiana del Farmaco

AIFA

3 - Manufacturing Operations - Active Substances GESTODENE	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances GUANFACINE HYDROCHLORIDE	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it

	material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **IDEBENONE**	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, sieving **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **INDACATEROL MALEATE**	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps

	drying,micronisation **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **INDAPAMIDE**	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it
SIS : 1738

VI
GMP

3 - Manufacturing Operations - Active Substances LATANOPROST	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: prostaglandines **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: Purification
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps filtration **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances LEVONORGESTREL	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it
SIS : 1738

	3.5.1. Physical processing steps drying, milling, micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
LEVONORGESTREL BUTYRATO

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
LOTEPREDNOL ETABONATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it
SIS : 1738

VI
GMP

Agenzia Italiana del Farmaco

AIFA

	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
MEMANTINE HYDROCHLORIDE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation,sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot

	numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
MIDODRINE HYDROCHLORIDE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, milling, micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
MOMETASONE FUROATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps:

	crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **MOMETASONE FUROATE MONOHYDRATE**	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it
SIS : 1738

VI
GMP

3 - Manufacturing Operations - Active Substances
NITAZOXANIDE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, milling **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
NOMEGESTROL ACETATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: cristallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving

	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
NORGESTIMATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

Agenzia Italiana del Farmaco

AIFA

3 - Manufacturing Operations - Active Substances PENTAZOCINE HYDROCHLORIDE	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances SALMETEROL XINAFOATE	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)

	3.5.3. Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
SULFAMETHYLTHIAZOLE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
TAFLUPROST

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements

	Other: prostaglandins **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: purification
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
TIBOLONE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the

	material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **TIOTROPIUM BROMIDE MONOHYDRATE**	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **TIOTROPIUM BROMIDE SOLVATE**	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation

Agenzia Italiana del Farmaco

AIFA

3.5	General Finishing Steps
	3.5.1. Physical processing steps drying **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
TRAVOPROST

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: prostaglandins **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
TRIMEGESTONE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
ZOPICLONE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1. Manufacture of active substance intermediates **3.1.2.** Manufacture of crude active substance **3.1.3.** Salt formation / Purification steps: crystallisatiion
3.5	**General Finishing Steps**
	3.5.1. Physical processing steps drying,micronisation, sieving

	3.5.2. Primary Packaging (enclosing / sealing the active substancewithin a packaging material which is in direct contact with the substance) **3.5.3.** Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

Name and address of the site:

Reparto distaccato - Laboratorio Chimico-Fisico - Via J.F. Kennedy, 19 - 20871 - VIMERCATE (MB)

Name of the active Substances manufactured or imported: ACTIVE SUBSTANCES

3 - Manufacturing Operations - Active Substances **ACTIVE SUBSTANCES**	
3.5	**General Finishing Steps**
	3.5.4. Other Only quality control laboratory
3.6	**Quality Control Testing**
	3.6.1. Physical / Chemical testing

Agenzia Italiana del Farmaco

AIFA

4. Other Activities - Active Substance:

Importation of:
11-ALPHA-HYDROXY CANRENONE (Confidential); ESTRADIOL HEMIHYDRATE (Confidential); ESTRONE (Confidential); GESTONORONE ACETATE (Confidential); LEVONORGESTREL ACETATE (Confidential); MEMANTINE HYDROCHLORIDE; PRASTERONE ACETATE (Confidential); PREDNISOLONE (Confidential)

Restrictions or clarifying remarks:

The Inspectorate adopted a risk-based approach for planning of inspections, therefore the validity of the GMP certificate for this manufacturing site is not more than 36 months from the last general GMP inspection, which was conducted on 2016/04/08. It will still be AIFA's right to re-evaluate the validity of the GMP certificate based on risk profile changes.
Imported Active Substances marked as confidential undergo further processing within the importing site.

Rome, 2016/09/16

Name and signature of the authorised person of the Competent Authority of Republic of Italy

Dott.ssa Isabella Marta
AIFA – Manufacturing Authorization Office

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmaco.it
SIS : 1738

VI
GMP